Next on tap for Meridian Bioscience‘s (NASDAQ:VIVO) illumigene molecular diagnostic testing platform is a test for Mycoplasma pneumonia, an infection of the lungs. The illumigene Mycoplasma test is ...
Scientists at Hackensack Meridian Health have developed a test that can detect multiple coronavirus variants within two-and-a-half hours, the Edison, N.J.-based system said April 1. The test is ...
CINCINNATI, Ohio — Meridian Bioscience’s European division will distribute in Italy a test for intestinal problems with plans to expand into France. The test, Quantum Blue Calprotectin, differentiates ...
CINCINNATI, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that it has initiated clinical trials for a new illumigene CMV molecular amplification test. This ...
(Reuters) - Meridian Bioscience Inc said its test to detect a common bacterial throat infection received marketing approval in the United States. Meridian said its molecular test can detect Group A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback